November 15, 2016 - By Dolores Ford · 0 Comments
Fibrocell Science Inc (NASDAQ:FCSC) institutional sentiment decreased to 0.61 in 2016 Q2. Its down -0.43, from 1.04 in 2016Q1. The ratio is negative, as 20 institutional investors opened new and increased holdings, while 33 sold and decreased holdings in Fibrocell Science Inc. The institutional investors in our partner’s database now own: 27.13 million shares, down from 30.54 million shares in 2016Q1. Also, the number of institutional investors holding Fibrocell Science Inc in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 18 Reduced: 15 Increased: 11 New Position: 9.
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The company has a market cap of $31.85 million. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. It currently has negative earnings. The Company’s product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
About 17,572 shares traded hands. Fibrocell Science Inc (NASDAQ:FCSC) has declined 72.27% since April 13, 2016 and is downtrending. It has underperformed by 76.19% the S&P500.
According to Zacks Investment Research, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma.”
Third Security Llc holds 1% of its portfolio in Fibrocell Science Inc for 16.62 million shares. Healthcare Value Capital Llc owns 147,769 shares or 0.21% of their US portfolio. Moreover, Msd Partners L.P. has 0.16% invested in the company for 2.08 million shares. The New York-based Qvt Financial Lp has invested 0.15% in the stock. Alpine Partners Vi Llc, a New York-based fund reported 32,057 shares.#img1#
Ratings analysis reveals 67% of Fibrocell Science’s analysts are positive. Out of 3 Wall Street analysts rating Fibrocell Science, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $14 while the high is $14.0. The stock’s average target of $14 is 1902.86% above today’s ($0.699) share price. FCSC was included in 3 notes of analysts from September 28, 2015. TH Capital initiated Fibrocell Science Inc (NASDAQ:FCSC) rating on Tuesday, December 22. TH Capital has “Buy” rating and $14.0 price target. Roth Capital initiated the stock with “Buy” rating in Tuesday, December 22 report. The stock of Fibrocell Science Inc (NASDAQ:FCSC) earned “Neutral” rating by Wedbush on Monday, September 28.
Fibrocell Science, Inc. (Fibrocell), incorporated on September 28, 1992, is an autologous cell and gene therapy company. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. The Company’s personalized biologics platform consists of approximately two separate product engines, each of which uses its autologous fibroblast technology. The Company’s Autologous Fibroblast Product Engine utilizes fibroblast cells to target the localized environment of skin and connective tissue, which are difficult to treat with systemic drug therapies due to limited blood flow to these areas. The Company’s Gene Therapy Product Engine integrates its autologous fibroblast technology with the synthetic biology technology. The Firm has approximately two gene-therapy product candidates in pre-clinical development, FCX-007 and FCX-013. The Firm leases and operates its own manufacturing facility located in Exton, Pennsylvania.
Another recent and important Fibrocell Science Inc (NASDAQ:FCSC) news was published by Marketwatch.com which published an article titled: “Fibrocell Science stock price target cut to $4 from $6 at Wedbush Securities” on April 17, 2011.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford